menu
    • menu
    [{"orgOrder":0,"company":"NAYA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"NY-700","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"NAYA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NAYA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NAYA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NAYA Therapeutics","sponsor":"Ionetix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Partnership","leadProduct":"NY-703","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"NAYA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NAYA Therapeutics \/ Ionetix","highestDevelopmentStatusID":"4","companyTruncated":"NAYA Therapeutics \/ Ionetix"},{"orgOrder":0,"company":"NAYA Therapeutics","sponsor":"Atley Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Partnership","leadProduct":"NY-703","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"NAYA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NAYA Therapeutics \/ Atley Solutions","highestDevelopmentStatusID":"4","companyTruncated":"NAYA Therapeutics \/ Atley Solutions"},{"orgOrder":0,"company":"NAYA Therapeutics","sponsor":"INVO Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Demerger","leadProduct":"NY-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NAYA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NAYA Therapeutics \/ INVO Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"NAYA Therapeutics \/ INVO Bioscience"},{"orgOrder":0,"company":"NAYA Therapeutics","sponsor":"NAYA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2025","type":"Partnership","leadProduct":"NY-703","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"NAYA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NAYA Therapeutics \/ NAYA Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"NAYA Therapeutics \/ NAYA Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by NAYA Therapeutics

    Menu

    NAYA Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NAYA Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            NAYA Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NY-703

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Alpha Nuclide

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Naya Partners Alpha Nuclide for GPC3 Astatine-211 Therapy in China for HCC

                            Details : Alpha Nuclide will supply 211At to NAYA Therapeutics for NY-703, a GPC3-targeting ²¹¹At alpha therapy for the treatment of residual disease & metastasis in hepatocellular carcinoma.

                            Product Name : NY-703

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            October 13, 2025

                            Lead Product(s) : NY-703

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Alpha Nuclide

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NAYA Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            NAYA Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NY-703

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Atley Solutions

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            NAYA to Partner With Atley to Accelerate Its Astatine-211 Radio Pharmaceuticals

                            Details : The partnership aims to accelerate the development and commercialization of NAYA's ²¹¹At radiopharmaceuticals, including NY-703, a GPC3-targeting a At-211 targeted alpha therapy.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            September 02, 2025

                            Lead Product(s) : NY-703

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Atley Solutions

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NAYA Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            NAYA Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NY-703

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Ionetix

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            NAYA Therapeutics Partners With IONETIX for Astatine-211 Targeted Alpha Therapies

                            Details : The partnership aims to supply Astatine-211 for NAYA's Lead Therapy, NY-703, GPC3-targeting ²¹¹At candidate, aiming to Enter Clinical Trials for Residual & Metastatic hepatocellular carcinoma.

                            Product Name : NY-703

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            August 21, 2025

                            Lead Product(s) : NY-703

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Ionetix

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            NAYA Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            NAYA Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NY-700

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NAYA Therapeutics Expands its Hepatocellular Carcinoma (HCC) Pipeline with First-in-Class GPC3-Targeted Astati...

                            Details : NY-700 consists of an Astatine-211 isotope conjugated to our GPC3-internalizing antibody through a proprietary linker.

                            Product Name : NY-700

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            June 17, 2025

                            Lead Product(s) : NY-700

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NAYA Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            NAYA Therapeutics

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NY-303

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : INVO Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Demerger

                            DEALS_DEV arrow-down

                            Naya Therapeutics Regains Rights to Cancer Immunotherapy for Clinical Progress

                            Details : NAYA Therapeutics to advance clinical development milestones for its portfolio of first and potential best-in-class candidates, including NY-303, a GPC3/NKp46/CD16 trifunctional antibody for HCC.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            May 29, 2025

                            Lead Product(s) : NY-303

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : INVO Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Demerger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth